AGTX OTC
Agentix Corp.
1W: +0.0%
1M: +0.0%
3M: -5.2%
YTD: -46.7%
1Y: -55.6%
3Y: -80.9%
5Y: -98.4%
$0.02
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.8M
52W Range0.0142-0.055
Volume188,637
Avg Volume14,190
Beta0.77
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEORiazul Huda
Employees2
SectorHealthcare
IndustryBiotechnology
IPO Date2015-08-21
Websiteagentixcorp.com
32932 Pacific Coast Highway
Dana Point, CA 92629
US
Dana Point, CA 92629
US
321 299 2014
About Agentix Corp.
Agentix Corp., a company in the clinical development phase, specializes in the discovery and commercialization of therapeutic agents aimed at treating metabolic disorders. Its pipeline includes two primary candidates: AGTX-2004, a peripherally-acting CB1 receptor antagonist, which has exhibited effectiveness in animal studies for both obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, also demonstrating positive results in animal models for obesity and non-alcoholic fatty liver diseases. The company was founded in 2013, initially known as FairWind Energy, Inc., before officially changing its name to Agentix Corp. in June 2019. Its operations are based in Dana Point, California.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Puzzo Thomas E | 0 | — | 2020-03-29 | |
| Grays Peak Ventures | P-Purchase | 767,000 | $1.02 | 2020-03-29 |
| Winterhalter Michael | P-Purchase | 150,000 | $1.02 | 2020-03-29 |
| Grays Peak Ventures | J-Other | 1,407,000 | $20.44 | 2020-02-24 |
| Winterhalter Michael | S-Sale | 10,015 | $20.44 | 2019-11-22 |